Keywords: Parkinson's disease. Teva. Lundbeck, Azilect, Patient share of treatments, Decision Resources, USA

Patient share of Teva/Lundbeck's Azilect for Parkinson's continues to grow

Article | 01 August 2012

Print This

Through examination of US patient-level claims data, that patient share of Azilect (rasagiline) - from Israel’s Teva Pharmaceutical ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in